Saturday 17 October 2026
Export JANX’s income statement to Excel — free account
Janux Therapeutics, Inc.
JANX Healthcare Biotechnology
Janux Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $10.0 million, down 5.55% from fiscal 2024. In the quarter to June 2026, revenue grew 2,238.7%, EPS grew 36.4% and free cash flow grew 150.6%, each against the same quarter a year earlier.
16.49
0.83
−4.79%
Follow JANX
| Dec '17 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | — | 4 | 4 | 2 |
P/E ratio |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | — | — | 21.34 | 7.61 | 7.69 | 45.12 | 11.61 |
P/S ratio |
— | — | — | 127.65 | 67.51 | 60.01 | 271.80 | 44.23 |
Altman Z″-Score (non-manufacturers) |
— | — | — | 33.80 | 11.25 | 13.09 | 32.65 | 26.48 |
P/FCF ratio |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
— | — | — | (44.29) | (48.80) | (48.99) | (172.07) | (29.96) |
P/B ratio |
— | — | — | 1.27 | 1.81 | 1.41 | 2.81 | 0.89 |
Price to Tangible BV |
— | — | — | 1.27 | 1.81 | 1.41 | 2.81 | 0.89 |
EV/Sales |
— | — | — | 24.55 | 29.54 | 17.45 | 174.98 | (5.76) |
EV/EBITDA |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.64 |
EV/Operating CF |
— | — | — | (5.26) | (5.93) | (2.79) | (42.29) | 1.35 |
EV/FCF |
— | — | — | (4.84) | (5.15) | (2.69) | (41.94) | 1.34 |
Quick Ratio |
— | 0.14 | 4.97 | 29.30 | 19.81 | 26.40 | 58.72 | 38.67 |
Current Ratio |
— | 0.14 | 5.05 | 29.46 | 20.14 | 26.80 | 59.21 | 39.04 |
Net Debt/EBITDA |
— | 0.17 | 1.62 | 11.37 | 4.78 | 4.37 | 9.55 | 5.58 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 |
Operating CF/Net income |
— | 0.96 | 0.64 | 0.52 | 0.68 | 0.87 | 0.64 | 0.72 |
Capex/Depreciation |
— | 0.00 | 0.00 | 25.12 | 4.80 | 0.32 | 0.04 | 0.07 |
Interest Coverage |
— | (16.18) | (23.51) | (128.13) | (16.64) | — | — | — |
| — | 35.46% | 60.08% | (18.58%) | (18.36%) | (17.53%) | (10.09%) | (11.48%) | |
| — | (1,179.38%) | (80.30%) | (16.50%) | (16.96%) | (15.66%) | (9.57%) | (11.02%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | 0.00% | (14,209.31%) | 0.00% | 0.00% |
Return on Tangible Assets |
— | 101.42% | (52.04%) | (8.94%) | (19.52%) | (16.98%) | (6.76%) | (11.90%) |
Average Days of Receivables |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 721.39% | 620.54% | 679.48% | 645.90% | 1,258.96% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 284.00% | 258.50% | 323.39% | 387.67% | 417.71% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 189.99% | 199.76% | 247.49% | 311.86% | 402.21% |
Graham Net Nets |
— | — | — | 0.78 | 0.50 | 0.65 | 0.35 | 1.09 |
Graham Number |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | — | — | (16.55%) | (10.84%) | (12.16%) | (2.39%) | (13.26%) |
Free Cash Flow Yield |
— | — | — | (3.98%) | (8.49%) | (10.81%) | (1.53%) | (9.74%) |
Revenue per Share |
— | 0.00 | 0.00 | 0.15 | 0.21 | 0.18 | 0.20 | 0.16 |
Operating CF per Share |
— | (5.72) | (4.77) | (0.72) | (1.03) | (1.15) | (0.82) | (1.33) |
Capex per Share |
— | 0.00 | 0.00 | (0.06) | (0.16) | (0.04) | (0.01) | (0.02) |
Free Cash Flow per Share |
— | (5.72) | (4.77) | (0.78) | (1.19) | (1.19) | (0.82) | (1.34) |
Cash per Share |
— | 0.98 | 8.54 | 15.94 | 7.89 | 7.82 | 19.07 | 15.60 |
Shareholders Equity per Share |
— | (5.90) | 7.63 | 15.57 | 7.73 | 7.82 | 19.03 | 15.44 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | (5.90) | 7.63 | 15.57 | 7.73 | 7.82 | 19.03 | 15.44 |
Free Cash Flow |
— | (3.83) | (4.37) | (18.46) | (49.37) | (52.42) | (44.17) | (83.28) |
Working Capital |
— | (3.97) | 12.88 | 364.22 | 315.93 | 336.21 | 1,016.21 | 950.89 |
Capital Expenditures |
— | — | — | (1.48) | (6.44) | (1.85) | (0.36) | (1.04) |
Net Current Asset Value |
— | (3.97) | 6.83 | 363.52 | 289.17 | 313.18 | 994.93 | 931.14 |
EV/EBIT |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.71 |
Capex to Sales |
— | — | — | 0.41 | 0.75 | 0.23 | 0.03 | 0.10 |
Price to Operating Income |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||
Depreciation/Fixed assets |
— | 0.29 | 0.08 | (0.04) | (0.19) | (0.82) | (1.75) | (4.04) |
Cash ROIC |
— | 116.35% | (29.52%) | (2.49%) | (7.62%) | (7.62%) | (2.16%) | (4.33%) |
Accounts Receivable Turnover |
— | — | 0.00 | 0.89 | 19.14 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Receivables |
— | — | 4.10 | 4.10 | 0.45 | — | — | — |
Average Payables |
— | 0.35 | 0.35 | 1.44 | 2.31 | 2.29 | 3.23 | 4.50 |
Average Assets |
— | 0.34 | 8.45 | 198.02 | 371.92 | 372.21 | 720.96 | 1,031.54 |
Average Common Equity |
— | (11.29) | (11.29) | 175.84 | 343.53 | 332.54 | 683.57 | 989.80 |
Columns are period end dates